Zinforo

C₂₂H₂₁N₈O₈PS₄684.70 g/mol

(6R,7R)-7-[[(2Z)-2-Ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 9852981.

Registration

Applicants: 1
Registrations: 1

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Pfizer Laboratories (Pty) Ltd	Zinforo	600 mg	460628	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Zinforo 600 MG EACH VIAL CONTAINS CEFTAROLINE FOSAMIL 600,0 mg	600 mg	46062846/20.1.1/0628	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading Wikipedia summary

SAHPRA documents

Professional information (PI)For healthcare professionalsZinforo 600 MG, Pfizer Laboratories (Pty) Ltd. SAHPRA's document for ZINFORO Patient information leaflet (PIL)For patients and carersZinforo 600 MG, Pfizer Laboratories (Pty) Ltd. SAHPRA's document for ZINFORO

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles